LabGenius combines artificial intelligence, robotic automation and synthetic biology to evolve next-generation protein therapeutics.

LabGenius develops therapeutics of high value for diseases of unmet need. The company deploys machine intelligence to model the relationship between DNA sequence and protein function, while improving the predictive accuracy of these models through experimental lab data generated through its smart robotic platform.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2019

• Founders

  • James Field

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • “As a startup, how fast we can move, how fast we can iterate, is central to everything.” @tgvashworth and… https://t.co/67SjYVgNdC@labgeni_us - 02:30 PM Apr 21st
  • Back in January, we welcomed Dan Foxler to the @labgeni_us team as a Principal Scientist 🔬 A few months on, we ca… https://t.co/5Sg3MLW08b@labgeni_us - 05:07 PM Apr 5th
  • 🧬Are you attending #BIOEuropeSpring and want to hear more about EVA™, our ML-driven protein engineering platform?… https://t.co/PVj1e0s7Kf@labgeni_us - 11:39 AM Mar 24th